News

Northwestern researchers were able to calm overactive neurons and restore neuronal activity, which could potentially slow the progression of disease.

New research reveals that the antidepressant fluoxetine does more than raise serotonin levels – it changes how brain cells use energy and rebuild their connections, potentially reopening the brain’s capacity to adapt.

Treatment for obesity in the UK could become a “two-tier system” where the most vulnerable patients miss out altogether.

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions.

Scientists have co-developed the world’s first product-ready, lab-produced, recombinant snakebite antivenom that protects against many of Africa’s most dangerous snakes and outperforms existing antivenoms.

Sertraline contributes to a modest improvement in core depression and anxiety symptoms within two weeks, a new analysis has found.

Researchers have developed a groundbreaking new chemotherapeutic agent, LiPyDau, which shows remarkable efficacy against multiple tumor types in preclinical studies.

New study shows that targeting an oft-drugged family of cell membrane receptors with biased modulators can expand potential drug targets and reduce side effects.

An under-appreciated cancer mutation has been found to block immune checkpoint inhibitor drugs, offering a new approach to treating "cold" tumors.

Enhancing continuous manufacturing of vaccines, researchers innovate a Raman spectroscopy tool for efficient quality control in production.